Etoposide therapy for testicular cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

During the past two decades, dramatic strides have been made in the treatment of metastatic testicular cancer. In the early 1970s, cisplatin, vinblastine, and bleomycin (PVB) produced durable complete remissions (CR) in approximately 70% of treated patients. In the early 1980s, etoposide emerged as the only drug with single-agent activity in cisplatin-refractory patients. Based on preclinical data demonstrating synergy of cisplatin plus etoposide, the two-drug combination proved to be a useful salvage therapy, curing approximately 25% of such patients. Further evaluation of etoposide as part of initial therapy by the Southeastern Cancer Study Group (SECSG) compared PVB with bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with metastatic germ cell tumors. Not only did BEP have significantly less toxicity, it proved to be superior to PBV in patients with advanced disease. Varying the dose and schedule of etoposide also may provide patients with potentially useful avenues of treatment. High-dose etoposide plus carboplatin in drug-refractory patients has produced durable CR in a cohort of treated patients; it is currently being evaluated as part of initial salvage therapy. The schedule dependency of etoposide in small cell lung cancer led us to evaluate daily oral administration of etoposide in patients refractory to previous etoposide therapy; objective response rates of approximately 15% to 25% were observed. In summary, etoposide remains an integral part of the treatment regimen for testis cancer. However, the incorporation of innovative dose and schedule combinations for etoposide may further improve its therapeutic index for this disease.

Original languageEnglish
Pages (from-to)220-224
Number of pages5
JournalCancer
Volume67
Issue number1 SUPPL.
StatePublished - 1991

Fingerprint

Testicular Neoplasms
Etoposide
Cisplatin
Bleomycin
Therapeutics
Salvage Therapy
Appointments and Schedules
Vinblastine
Germ Cell and Embryonal Neoplasms
Carboplatin
Small Cell Lung Carcinoma
Drug Combinations
Pharmaceutical Preparations
Oral Administration

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Etoposide therapy for testicular cancer. / Loehrer, Patrick.

In: Cancer, Vol. 67, No. 1 SUPPL., 1991, p. 220-224.

Research output: Contribution to journalArticle

Loehrer, P 1991, 'Etoposide therapy for testicular cancer', Cancer, vol. 67, no. 1 SUPPL., pp. 220-224.
Loehrer, Patrick. / Etoposide therapy for testicular cancer. In: Cancer. 1991 ; Vol. 67, No. 1 SUPPL. pp. 220-224.
@article{6d9a153ddccd4251b22230ccd4f5ad7f,
title = "Etoposide therapy for testicular cancer",
abstract = "During the past two decades, dramatic strides have been made in the treatment of metastatic testicular cancer. In the early 1970s, cisplatin, vinblastine, and bleomycin (PVB) produced durable complete remissions (CR) in approximately 70{\%} of treated patients. In the early 1980s, etoposide emerged as the only drug with single-agent activity in cisplatin-refractory patients. Based on preclinical data demonstrating synergy of cisplatin plus etoposide, the two-drug combination proved to be a useful salvage therapy, curing approximately 25{\%} of such patients. Further evaluation of etoposide as part of initial therapy by the Southeastern Cancer Study Group (SECSG) compared PVB with bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with metastatic germ cell tumors. Not only did BEP have significantly less toxicity, it proved to be superior to PBV in patients with advanced disease. Varying the dose and schedule of etoposide also may provide patients with potentially useful avenues of treatment. High-dose etoposide plus carboplatin in drug-refractory patients has produced durable CR in a cohort of treated patients; it is currently being evaluated as part of initial salvage therapy. The schedule dependency of etoposide in small cell lung cancer led us to evaluate daily oral administration of etoposide in patients refractory to previous etoposide therapy; objective response rates of approximately 15{\%} to 25{\%} were observed. In summary, etoposide remains an integral part of the treatment regimen for testis cancer. However, the incorporation of innovative dose and schedule combinations for etoposide may further improve its therapeutic index for this disease.",
author = "Patrick Loehrer",
year = "1991",
language = "English",
volume = "67",
pages = "220--224",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Etoposide therapy for testicular cancer

AU - Loehrer, Patrick

PY - 1991

Y1 - 1991

N2 - During the past two decades, dramatic strides have been made in the treatment of metastatic testicular cancer. In the early 1970s, cisplatin, vinblastine, and bleomycin (PVB) produced durable complete remissions (CR) in approximately 70% of treated patients. In the early 1980s, etoposide emerged as the only drug with single-agent activity in cisplatin-refractory patients. Based on preclinical data demonstrating synergy of cisplatin plus etoposide, the two-drug combination proved to be a useful salvage therapy, curing approximately 25% of such patients. Further evaluation of etoposide as part of initial therapy by the Southeastern Cancer Study Group (SECSG) compared PVB with bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with metastatic germ cell tumors. Not only did BEP have significantly less toxicity, it proved to be superior to PBV in patients with advanced disease. Varying the dose and schedule of etoposide also may provide patients with potentially useful avenues of treatment. High-dose etoposide plus carboplatin in drug-refractory patients has produced durable CR in a cohort of treated patients; it is currently being evaluated as part of initial salvage therapy. The schedule dependency of etoposide in small cell lung cancer led us to evaluate daily oral administration of etoposide in patients refractory to previous etoposide therapy; objective response rates of approximately 15% to 25% were observed. In summary, etoposide remains an integral part of the treatment regimen for testis cancer. However, the incorporation of innovative dose and schedule combinations for etoposide may further improve its therapeutic index for this disease.

AB - During the past two decades, dramatic strides have been made in the treatment of metastatic testicular cancer. In the early 1970s, cisplatin, vinblastine, and bleomycin (PVB) produced durable complete remissions (CR) in approximately 70% of treated patients. In the early 1980s, etoposide emerged as the only drug with single-agent activity in cisplatin-refractory patients. Based on preclinical data demonstrating synergy of cisplatin plus etoposide, the two-drug combination proved to be a useful salvage therapy, curing approximately 25% of such patients. Further evaluation of etoposide as part of initial therapy by the Southeastern Cancer Study Group (SECSG) compared PVB with bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with metastatic germ cell tumors. Not only did BEP have significantly less toxicity, it proved to be superior to PBV in patients with advanced disease. Varying the dose and schedule of etoposide also may provide patients with potentially useful avenues of treatment. High-dose etoposide plus carboplatin in drug-refractory patients has produced durable CR in a cohort of treated patients; it is currently being evaluated as part of initial salvage therapy. The schedule dependency of etoposide in small cell lung cancer led us to evaluate daily oral administration of etoposide in patients refractory to previous etoposide therapy; objective response rates of approximately 15% to 25% were observed. In summary, etoposide remains an integral part of the treatment regimen for testis cancer. However, the incorporation of innovative dose and schedule combinations for etoposide may further improve its therapeutic index for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0025962792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025962792&partnerID=8YFLogxK

M3 - Article

C2 - 1984823

AN - SCOPUS:0025962792

VL - 67

SP - 220

EP - 224

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1 SUPPL.

ER -